ONCIMMUNE HOLDINGS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.48 GBX | -5.56% |
|
+18.97% | +9.05% |
| Feb. 29 | EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout | AN |
| Feb. 29 | Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024 | CI |
| Sales 2020 | 509K 631K | Sales 2021 | 3.72M 4.62M | Capitalization | 129M 160M |
|---|---|---|---|---|---|
| Net income 2020 | -8M -9.92M | Net income 2021 | -4M -4.96M | EV / Sales 2020 | 191 x |
| Net Debt 2020 | 4.04M 5.01M | Net Debt 2021 | 837K 1.04M | EV / Sales 2021 | 34.9 x |
| P/E ratio 2020 |
-11
x | P/E ratio 2021 |
-26.1
x | Employees | 52 |
| Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 71.2% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +10.23% | ||
| 1 week | +38.57% | ||
| Current month | +37.26% | ||
| 1 month | +61.67% | ||
| 3 months | +8.58% | ||
| 6 months | +70.67% | ||
| Current year | +15.48% |
1 week
23.25
31.00
1 month
16.1831.00
Current year
15.8231.00
1 year
13.0045.00
3 years
13.00253.55
5 years
13.00261.63
10 years
13.00261.63
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 23-07-31 | |
Martin Hudson
DFI | Director of Finance/CFO | - | 23-09-03 |
James R. Jett
CTO | Chief Tech/Sci/R&D Officer | - | 15-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Goold
BRD | Director/Board Member | 52 | 23-01-12 |
Timothy Bunting
BRD | Director/Board Member | 61 | 15-10-08 |
Ron Kirschner
COO | Chief Operating Officer | - | 20-04-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 27.48 | -5.56% | 20 505 |
| 24-04-18 | 29.1 | +10.23% | 215,861 |
| 24-04-17 | 26.4 | +4.76% | 468 |
| 24-04-16 | 25.2 | 0.00% | 36,374 |
| 24-04-15 | 25.2 | +9.09% | 140,326 |
Delayed Quote London S.E., April 18, 2024 at 11:35 am EDT
More quotes
Oncimmune Holdings plc is a United Kingdom-based immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiaries include Oncimmune Americas LLC, Oncimmune Germany GmbH, and Oncimmune LLC, among others.
Sector
Pharmaceuticals
Calendar
2024-10-30
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.48% | 26.88M | |
| +10.21% | 9.12B | |
| -15.94% | 4.8B | |
| +18.47% | 3.72B | |
| +1.89% | 3.8B | |
| +28.61% | 2.58B | |
| -24.63% | 2.36B | |
| -29.37% | 2.11B | |
| +2.55% | 1.86B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- ONC Stock
